OncoVision, Inc.

OncoVision, Inc. specializes in innovative medical imaging technology, focusing on advanced diagnostic solutions for cancer detection and treatment, including specialized devices for breast cancer and neurodegenerative diseases. Founded in 2003, OncoVision, Inc. is based in Valencia, Spain, and develops cutting-edge medical imaging devices.

The company was acquired by Bruker Daltonics in September 2016 for an undisclosed amount. Noriel Pavon is the founder of OncoVision, bringing expertise from previous ventures to drive the company's growth in cancer diagnostics. Oncovision is at the forefront of innovative medical imaging, specializing in advanced devices tailored for the diagnosis and treatment of cancer. The company’s core product offerings include Mammi, a Breast PET imaging system designed for precise breast cancer detection; Sentinella, which enhances lymphatic mapping for surgical procedures; Wprobe, a handheld device providing real-time imaging for tumor localization; and CareMiBrain, aimed at addressing Alzheimer's disease through molecular imaging techniques.

These products serve a diverse client base, including surgeons, radiologists, oncologists, and nuclear medicine specialists in hospitals and clinics. Oncovision's innovative imaging solutions are marketed primarily in Europe and North America, where the demand for early cancer detection and treatment options is escalating. Oncovision’s revenue for the most recent year, 2022, was USD 1. 62 mn, with an EBITDA of USD -483,056.

The company's revenue model is structured around direct sales of its specialized medical imaging devices to healthcare professionals and institutions. Transactions typically involve direct procurement by healthcare providers, who acquire products such as Mammi and Sentinella for their clinical applications. Revenue generation occurs through one-time purchases and potential service agreements for product maintenance and updates. The company also engages in collaborations with medical institutions for research and development purposes, creating opportunities for additional revenue streams through partnerships.

Oncovision’s flagship products, including Wprobe and CareMiBrain, play a significant role in driving sales, as they address critical needs in cancer and neurodegenerative disease diagnostics. OncoVision is focused on launching new products and expanding into new markets. Future product developments are expected to enhance its diagnostic capabilities, although specific release dates have not been disclosed. The company seeks to penetrate additional European and North American markets by 2025.

Recent funding, resulting from its acquisition in 2016, is anticipated to support these initiatives by facilitating research and development activities aimed at enhancing its product offerings and expanding its market reach.